Wade T. Iams, MD, of Tennessee Oncology, says the stability of skin toxicity rates across 8.3 months of COPERNICUS follow-up, with 86% of participants still on study, gives him the most confidence in subcutaneous amivantamab plus lazertinib, and the near elimination of infusion reactions carries the most weight.
Luis E. Raez, MD, of Miami Cancer Institute, reports that with extended COPERNICUS follow-up, rash in the first 4 months of subcutaneous amivantamab plus lazertinib was lower than in MARIPOSA, similar across age groups, and less often grade 2 or higher, with lower cumulative incidence by 1 year.
Wade T. Iams, MD, of Tennessee Oncology, presents extended COPERNICUS follow-up: 274 US participants have received subcutaneous amivantamab plus lazertinib, and 214 enrolled at least 4 months before the data cutoff.
Luis E. Raez, MD, of Miami Cancer Institute, summarizes the early COPERNICUS conclusions: enhanced prophylaxis with subcutaneous amivantamab plus lazertinib led to low rates of severe rash, thrombosis, and infusion reactions, though shorter follow-up limits inference.
Luis E. Raez, MD, of Miami Cancer Institute, and Wade T. Iams, MD, of Tennessee Oncology, consider how to interpret descriptive comparisons between COPERNICUS and MARIPOSA, given median follow-up of 4.9 vs 22 months and no formal statistical testing.
Wade T. Iams, MD, of Tennessee Oncology, reviews early COPERNICUS safety data, in which patients receiving subcutaneous amivantamab plus lazertinib also received intensive skin prophylaxis.
Luis E. Raez, MD, of Miami Cancer Institute, reviews baseline characteristics from the early safety analysis of COPERNICUS, which tested subcutaneous amivantamab plus lazertinib in epidermal growth factor receptor–mutated lung cancer.
Wade T. Iams, MD, of Tennessee Oncology, walks through the design of COPERNICUS, a single-arm US study of subcutaneous amivantamab plus lazertinib in patients with exon 19 deletion or L858R epidermal growth factor receptor mutations.
Wade T. Iams, MD, of Tennessee Oncology, and Luis E. Raez, MD, of Miami Cancer Institute, discuss anticoagulation after the 4-month window and what happens when patients stop skin prophylaxis early on amivantamab plus lazertinib.
COPERNICUS updates suggest subcutaneous amivantamab plus lasertinib fits real-world EGFR lung cancer care, with skin and clot prophylaxis.
New data show subcutaneous amivantamab plus lasertinib simplifies EGFR-mutant lung cancer care with proactive skin and clot prevention.
Two clinical scenarios illustrated shared decision-making in practice: a 58-year-old woman with TP53 mutation, L858R, and asymptomatic brain metastases drew unanimous consensus for treatment intensification with either FLAURA2 or MARIPOSA, given her high-risk features and flexible schedule.
The debate examined whether amivantamab-lazertinib or osimertinib-chemotherapy more favorably reshapes resistance biology, with the MARIPOSA team citing data showing lower rates of MET amplification (7.3% vs. 13.1%) and secondary EGFR mutations (1.4% vs. 7.6%) compared to osimertinib monotherapy, alongside a potential immune-activating effect of amivantamab and a possible curve-flattening signal suggesting disease course modification.
Panelists agreed that subcutaneous amivantamab represents meaningful progress over the IV formulation, nearly eliminating infusion reactions, reducing dosing frequency to every four weeks, and lowering high-grade dermatologic toxicity, although grade 1-2 rash and the burden of the COCOON prophylaxis regimen remain relevant considerations for patients.
The debate centered on CNS efficacy comparisons between MARIPOSA and FLAURA2, with the key distinction being that MARIPOSA mandated serial brain MRIs for all patients, enabling full intracranial PFS analysis across all 429 participants, whereas FLAURA2 only required serial imaging in patients with baseline CNS metastases, limiting the robustness of its CNS data.
The TOP trial, a phase three study focused exclusively on TP53-mutant EGFR-mutant non-small cell lung cancer, validated the FLAURA2 findings in this high-risk subset, showing a striking PFS benefit of 34.0 versus 15.6 months (HR 0.44) for osimertinib plus chemotherapy over monotherapy, with a favorable duration of response of 32.7 versus 15.9 months, though overall survival data remain immature.
The FLAURA2 phase three trial demonstrated that adding platinum-based chemotherapy to osimertinib significantly improved outcomes over osimertinib monotherapy in first-line EGFR-mutant non-small cell lung cancer, with a median PFS of 29.4 versus 19.9 months and a statistically significant overall survival benefit of 47.5 versus 37.6 months.
The COPERNICUS study, an ongoing phase two trial, evaluated amivantamab-based regimens in EGFR-mutant non-small cell lung cancer across two cohorts, first-line and post-osimertinib progression, with a key focus on implementing mandatory prophylactic skin and DVT regimens, resulting in dramatically lower rash rates (4% grade 3+) compared to the original MARIPOSA trial.
Panelists discuss the pivotal MARIPOSA trial, which examined combining amivantamab with lazertinib versus osimertinib monotherapy, showing improvements in progression-free survival (23.7 vs. 16.6 months), overall survival, CNS efficacy, and particularly strong benefits in high-risk subgroups such as TP53-mutant patients. Safety data from the trial highlighted the importance of prophylactic measures, especially for rash and other adverse events, noting that with current prophylaxis protocols, serious toxicity rates have been significantly reduced compared to the original study.
Misako Nagasaka, MD, PhD, summarizes the key takeaways: proactive AE management, CNS vigilance, and strategic sequencing as hallmarks of modern care for EGFR-mutant NSCLC.
The discussion underscores the role of multidisciplinary coordination in maintaining adherence, quality of life, and long-term therapeutic benefit.
Experts debate when to introduce chemotherapy, how to manage its cumulative toxicity, and how to de-escalate maintenance regimens.
The panel explores integrating molecular data to guide therapy selection and optimize sequencing strategies after resistance emerges.
A second case illustrates clinical decision-making after progression on osimertinib, highlighting diagnostic re-biopsy and ctDNA testing.
The conversation shifts to how dual EGFR-MET inhibition reduces resistance mutations and molecular heterogeneity compared with osimertinib monotherapy.
The panel reviews components of the COCOON prophylactic regimen and the safe use of temporary dose modifications to maintain adherence.
Discussion centers on early dermatologic AEs with amivantamab plus lazertinib, emphasizing prevention protocols and staff education.
The physicians share real-world imaging schedules, triggers for adding local therapy, and lessons from serial MRI data in the MARIPOSA trial.
The panel examines a 59-year-old woman with small brain metastases, addressing therapy selection to balance CNS control, survival, and quality of life.
Experts discuss applying emerging evidence from MARIPOSA and FLAURA2 to first-line decision-making in EGFR-mutated disease.
July 20th 2026
